Semaglutide
From $299/mo with medication included, and every GLP-1 ships the same day.
Check my BMI eligibilityA licensed clinician reviews your health history before anything is prescribed.
Start a free consultationCellular support
ApoB, Lp(a), hs-CRP and more, reviewed by a licensed clinician.
Start with a free consultation$199 for 3 or more pets. You only pay if the clinician approves your letter.
Get your ESA letter$229 for 3 dogs. For housing and travel with a trained psychiatric service dog.
Get your PSD letterLabs & testing
Hair, skin & wellness
Mobile IV therapyIn 2024, Lilly launched the Zepbound vial format as a self-pay alternative to the KwikPen — same FDA-approved tirzepatide, lower price, vial-and-syringe delivery. For members who don't need the auto-injector format and want brand Zepbound at a better price, this is the path.
Brand tirzepatide for less — Lilly's response to the compounded tirzepatide market.
In late 2024, Eli Lilly introduced the Zepbound vial format — the same FDA-approved tirzepatide molecule as the KwikPen, but in a single-dose glass vial that you draw into a separate syringe. The vial format launched at a substantially lower cash-pay price than the KwikPen, positioning it as a direct competitive option to compounded tirzepatide.
For the right member, this is a meaningful win. You get brand-name FDA approval (which matters for some insurance contexts and personal preference), the full SURMOUNT trial efficacy data, the new sleep apnea indication, and Lilly's manufacturing quality — at a price that's competitive with compounded options.
What you trade off compared to the KwikPen: a slightly more involved injection process. You draw the dose from the vial into a syringe, expel air, and self-inject. For members who already inject medications (other GLP-1, insulin, fertility, immunotherapy), this is routine. For first-time injectors, the KwikPen format is gentler.
HealifyNow prescribes Zepbound vials for members who want brand-name FDA-approved tirzepatide at a lower price point than the KwikPen. The $399/month program includes monthly clinician visits, medication supply, and ongoing follow-up. The free initial consultation determines which format best fits you.
The vial format is Lilly's cash-pay alternative to the KwikPen at a meaningfully lower price.
Drawing from a vial and injecting with a separate syringe is straightforward — but it's a step beyond auto-injector ease.
Same molecule, same FDA approval, same SURMOUNT trial data, same mechanism. The format doesn't change the medication.
Some members specifically want brand Zepbound for FDA-traceable manufacturing rather than compounded.
From your first message to your medication arriving at your door — clinician-guided, every step.
A care team member meets with you to understand your goals, medical history, and treatment preferences. The first visit is no-cost and no-commitment — we want you to be confident before moving forward.
Connect by secure video or phone with a U.S.-licensed physician or nurse practitioner who reviews your full picture — labs, prior treatments, current medications, and lifestyle — and decides what is clinically appropriate.
If your clinician determines treatment is right for you, they issue a prescription that goes to a licensed U.S. pharmacy. We coordinate discreet shipping, or you can fill it locally. Follow-up visits are built in.
Tirzepatide is the same molecule whether delivered via KwikPen or vial. It activates two incretin receptors:
GLP-1 receptor activation — same mechanism as semaglutide. Appetite suppression in the hypothalamus, slowed gastric emptying, glucose-dependent insulin release, glucagon suppression.
GIP receptor activation — distinct from GLP-1. Improves insulin sensitivity, increases fat oxidation (lipolysis), and adds weight-loss effect that semaglutide alone doesn't produce.
The dual mechanism is why tirzepatide outperformed semaglutide in head-to-head trials (SURMOUNT-5, late 2024). At maximum doses, tirzepatide produced approximately 20% body weight loss versus approximately 14% for semaglutide at 72 weeks.
The 2024 FDA approval for obstructive sleep apnea (based on SURMOUNT-OSA) made Zepbound the first medication approved for OSA. Many members on Zepbound reduce or eliminate CPAP need with treatment.
Your clinician will review every relevant detail with you. Here are the most important points to know up front.
Nausea and constipation are most common during dose increases. Slow titration is key.
Personal or family history of MTC or MEN2 contraindicates.
Discontinue 2 months before planned conception.
Use the supplied syringes, follow draw-up protocol, dispose of needles properly. Your care team trains you.
All medications must be prescribed by a licensed provider based on medical necessity. Treatment is not suitable for everyone. Results may vary.
What you receive. Single-dose glass vials (one per weekly dose) plus disposable syringes, alcohol wipes, and a sharps container. Your care team includes a written guide and a brief video for the first injection.
Drawing the dose. Wipe the vial top with alcohol. Pull the syringe plunger to the dose mark, insert the needle, push air into the vial, invert, and draw the dose. Tap any air bubbles to the top and gently push them out. Total time once practiced: 30-60 seconds.
The injection. Same as any subcutaneous injection — abdomen, thigh, or upper arm. Pinch a small fold of skin, insert the needle at 90 degrees, push the plunger steadily, withdraw. Dispose of the syringe in your sharps container.
Storage. Refrigerate unused vials. Once a vial is in use, it can stay at room temperature briefly during the injection then return to the fridge if multi-use. Single-use vials are simply disposed after the injection.
Dose titration. Same schedule as KwikPen: 2.5 mg for 4 weeks, then 5 mg, with 2.5 mg increases every 4 weeks based on tolerance and response, up to 15 mg maximum.
Get a fast read on whether this is worth a deeper conversation.
Patients served across the U.S.
Member satisfaction with care team
Average review rating
From visit to medication shipment
We built HealifyNow because telehealth done badly is everywhere — and telehealth done right still feels rare. Here is what makes us different.
No waiting rooms, no faxed forms, no insurance hoops. Quick consults, simple intake, prescriptions handled digitally.
Real physicians, nurse practitioners, and specialists with active licenses. Not chatbots, not offshore call centers.
Medications ship from licensed U.S. pharmacies in plain packaging. Most orders arrive in 2-5 business days.
Reach a real human seven days a week. Most messages get a clinical reply within a few hours, not days.
HealifyNow prescriptions are reviewed and authorized by independently licensed physicians — real doctors with real credentials from top medical institutions in the United States.
A board-certified physician who brings a rigorous, pharmacology-driven lens to longevity medicine and weight management.
A Columbia-trained physician and former collegiate athlete focused on metabolic function, body composition, and healthspan.
A board-certified OB-GYN and ACOG Fellow with more than four decades of experience in women's health.
Real people, real results. Names and details published with permission.
"Tried compounded tirzepatide for 6 months — worked fine. When Lilly released the vial format, I switched for the FDA-brand assurance at a similar price. Same results, more confidence about supply chain."
"I already inject insulin daily. The vial format isn't intimidating to me. Saved money over the KwikPen and got brand Zepbound. 26 lbs down in 4 months."
"Lilly's vial launch was the answer I was waiting for. Wanted brand-name FDA approval without the KwikPen premium. Care team trained me on draw-up over video. Routine now."
HealifyNow makes it easy to move forward with confidence. Here are the answers to what people ask us most.
Lilly launched the vials at a substantially lower cash-pay price than the KwikPen. Through HealifyNow's program, the vial format is $399/month inclusive — competitive with compounded tirzepatide.
Yes. Same tirzepatide molecule, same FDA approval, same dose strengths, same efficacy. Only the delivery format differs.
It's a few extra steps — draw, expel air, inject — versus the KwikPen's one-click design. Members who've injected before (insulin, fertility meds, other GLP-1) usually find it easy. First-time injectors often prefer the KwikPen.
No. Syringes are single-use. We provide enough syringes for each weekly dose and a sharps container for disposal.
Mixed coverage — some commercial insurance covers Zepbound for weight management with prior authorization (the vial and KwikPen are coded the same way). Medicare typically doesn't cover weight-loss medications. We help check.
Yes — same medication. Many members switch formats based on travel needs (KwikPens easier to bring on trips) or cost considerations.
Brand Zepbound (vial or KwikPen) is manufactured by Lilly under FDA approval and oversight. Compounded tirzepatide is produced by licensed U.S. 503A and 503B compounding pharmacies — same active molecule, different manufacturing pathway and regulatory framework.
Each vial is single-use, containing one weekly dose. You receive one vial per week of your dose strength.
Book a free consultation, answer a short health questionnaire, then meet a licensed clinician by secure video or phone. If Zepbound vials is medically appropriate, your clinician sends the prescription to a licensed U.S. pharmacy and it ships to your door.
Yes. Telehealth prescribing is legal when a licensed clinician evaluates you first. Zepbound vials is only prescribed when it's clinically appropriate, and it's filled by a licensed U.S. pharmacy.
Zepbound vials is typically prescribed for adults with a BMI of 30 or higher, or 27 or higher with a weight-related condition such as high blood pressure, type 2 diabetes or sleep apnea. Your clinician reviews your health history, current medications and goals before deciding whether it's right for you.
Many members meet a clinician within a few days of booking. If Zepbound vials are prescribed, it ships the same day in discreet packaging.
Your clinician reviews your medical history, current medications, past treatments and goals by secure video or phone, explains the benefits and side effects, and agrees a plan with you. Labs may be ordered if needed.
Sometimes. Depending on your history, your clinician may ask for recent results or order a lab panel before prescribing Zepbound vials. Lab testing can be arranged at draw sites nationwide.
The most common side effects are nausea, diarrhea, constipation, vomiting and reduced appetite, usually strongest when starting or increasing the dose. Your clinician adjusts dosing and checks in to help you manage them.
Book a free consultation. We'll help you choose between the vial and KwikPen based on your situation.